Phenylalanine

Evidence Level: L5

Predicted Indications: 2

Phenylalanine

Pharmacist Assessment Report

Phenylalanine: From Unspecified Original Indication to Sclerosing Cholangitis

One-Sentence Summary

Phenylalanine is an essential aromatic amino acid, supplied in Australia as oral powder sachets, and no approved indication text is recorded for it in the data compiled for this report. The TxGNN model predicts it may be effective for sclerosing cholangitis, but this rests on a network-based score alone, with 0 clinical trials and 3 publications that do not show a therapeutic effect.

Quick Overview

Item	Content
Original Indication	Not recorded in the data compiled for this report
Predicted New Indication	Sclerosing cholangitis
TxGNN Prediction Score	0.9943
Evidence Level	L5
Australia Market Status	Listed on the PBS Schedule (2 of 2 items) – TGA (ARTG) registration status is not included in this data
Number of PBS Items	2 (valid: 2)
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available. Phenylalanine is a dietary amino acid and a precursor of tyrosine. The data compiled for this report do not record an approved indication, so the link between an original use and the predicted one cannot be assessed.

The three publications retrieved do not support a therapeutic role:

One cohort study examined plasma tyrosine, a downstream amino acid, and fatigue in primary biliary cirrhosis and primary sclerosing cholangitis. This is an association, not a treatment effect.
One study profiled the serum metabolic signature of cholangiocarcinoma. This is a biomarker study in a different disease.
One paper described a radioimmunoassay for a formylated bacterial peptide (fMLP), which is a different compound from L-phenylalanine used as a drug.

Aromatic amino acid metabolism may be altered in cholestatic liver disease, but that is a disease-state observation and not a rationale for supplementation. The high score most likely reflects network proximity rather than a biological mechanism.

A second prediction, congenital prothrombin deficiency (score 0.9926), has no clinical trials or literature. It is a monogenic coagulation factor II disorder treated with replacement therapy, and there is no known mechanism by which phenylalanine would correct it.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15790420	2005	Cohort	BMC Gastroenterology	Examined the relation between plasma tyrosine and fatigue in primary biliary cirrhosis and primary sclerosing cholangitis; an association with a downstream amino acid, not a treatment effect
32025163	2020	Cohort	Journal of Clinical and Experimental Hepatology	Serum metabolic signature of cholangiocarcinoma in a UK cohort; biomarker study in a different disease
2103382	1990	Assay development	Journal of Gastroenterology and Hepatology	Radioimmunoassay for a formylated bacterial peptide (fMLP) and its enterohepatic circulation; not about L-phenylalanine as a drug

Australia Market Information

ARTG Number	Product Name	Dosage Form	Approved Indication
ARTG 9384X	Phenylalanine 50	Oral powder sachets, 4 g containing 50 mg phenylalanine, 30	Not recorded
ARTG 11832R	TYR Sphere20	Oral powder sachets, 35 g, 30	Not recorded

Safety Considerations

Contraindications flagged in the knowledge graph (drug-disease links from the TxGNN knowledge graph, not product label text):
- Phenylketonuria and other disorders of phenylalanine metabolism
- Kidney disease, including chronic kidney disease, chronic renal failure, end stage renal failure, nephrolithiasis and nephrocalcinosis
- Heart and cardiovascular disease, ventricular fibrillation and digitalis poisoning
- Hypercalcaemia-related conditions, including sarcoidosis and humoral hypercalcaemia of malignancy
- Phosphorus metabolism disease, acute urate nephropathy and pyoureter

Please refer to the TGA-approved Product Information (PI) for label warnings, contraindications and drug interactions, as none were available in the data compiled for this report.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN score is very high, but it is a network-based prediction only, with no clinical trials and no literature showing that phenylalanine treats sclerosing cholangitis. No plausible therapeutic mechanism is established, and the knowledge graph flags several relevant contraindications, including kidney and cardiovascular disease.

To proceed, the following is needed:

Mechanism of action data (for example from DrugBank) and a plausible rationale linking phenylalanine to sclerosing cholangitis
Approved indication and label information for both ARTG entries, including PI warnings and contraindications
Preclinical or clinical evidence of a therapeutic effect, beyond metabolic marker studies
A safety assessment for patients with liver disease, who may also have renal or cardiovascular comorbidities
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.